Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates
Zura Bio reported Q3 2026 results with a net loss of $25.8 million, or $0.20 per share, versus $20.0 million a year earlier, with no revenue as a clinical-stage biotech. Cash stood at $187.7 million as of September 30, 2026, which management expects to fund operations through at least the end of 2028 -- covering all three planned tibulizumab readouts without near-term financing risk.
Key figures
- Revenue
- 0
- Net loss
- 25800000
- Ga expense
- 9300000
- Rd expense
- 19500000
- Cash runway
- through at least end of 2028
- Shares outstanding
- 96306411
- Net loss prior year
- 20000000
- Tibusure enrollment
- 91
- Cash and equivalents
- 187700000
- Ga expense prior year
- 7600000
- Rd expense prior year
- 11900000
- Tibushield enrollment
- 247
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.